Key references: Indications for endocarditis prophylaxis

  • Baskerville CA, Hanrahan BB, Burke AJ, Holwell AJ, Remond MG, Maguire GP. Infective endocarditis and rheumatic heart disease in the north of Australia. Heart Lung Circ 2012;21(1):36-41. https://www.ncbi.nlm.nih.gov/pubmed/21924682
  • Chen SJ, Liu CJ, Chao TF, Wang KL, Wang FD, Chen TJ, et al. Dental scaling and risk reduction in infective endocarditis: a nationwide population-based case-control study. Can J Cardiol 2013;29(4):429–33. https://www.ncbi.nlm.nih.gov/pubmed/22717251
  • Franklin M, Wailoo A, Dayer MJ, Jones S, Prendergast B, Baddour LM, et al. The cost-effectiveness of antibiotic prophylaxis for patients at risk of infective endocarditis. Circulation 2016;134(20):1568–78. https://www.ncbi.nlm.nih.gov/pubmed/27840334
  • Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015;36(44):3075–128. https://www.ncbi.nlm.nih.gov/pubmed/26320109
  • Janszky I, Gemes K, Ahnve S, Asgeirsson H, Moller J. Invasive procedures associated with the development of infective endocarditis. J Am Coll Cardiol 2018;71(24):2744–52. https://www.ncbi.nlm.nih.gov/pubmed/29903348
  • Katzenellenbogen JM, Bond-Smith D, Seth RJ, Dempsey K, Cannon J, Stacey I, et al. Contemporary incidence and prevalence of rheumatic fever and rheumatic heart disease in Australia using linked data: the case for policy change. J Am Heart Assoc 2020;9(19):e016851. https://www.ncbi.nlm.nih.gov/pubmed/32924748
  • Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017;70(2):252–89. https://www.ncbi.nlm.nih.gov/pubmed/28315732
  • Ostergaard L, Valeur N, Ihlemann N, Bundgaard H, Gislason G, Torp-Pedersen C, et al. Incidence of infective endocarditis among patients considered at high risk. Eur Heart J 2018;39(7):623–9. https://www.ncbi.nlm.nih.gov/pubmed/29244073
  • RHDAustralia (ARF/RHD writing group). The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease (3rd edition). Darwin, NT: RHD Australia; 2020. https://www.rhdaustralia.org.au/arf-rhd-guideline
  • Thornhill MH, Dayer MJ, Cahill TJ. Infective endocarditis after invasive medical and surgical procedures. J Am Coll Cardiol 2018;71(24):2753–5. https://www.ncbi.nlm.nih.gov/pubmed/29903349
  • Thornhill MH, Dayer MJ, Prendergast B, Baddour LM, Jones S, Lockhart PB. Incidence and nature of adverse reactions to antibiotics used as endocarditis prophylaxis. J Antimicrob Chemother 2015;70(8):2382–8. https://www.ncbi.nlm.nih.gov/pubmed/25925595
  • Thornhill MH, Jones S, Prendergast B, Baddour LM, Chambers JB, Lockhart PB, et al. Quantifying infective endocarditis risk in patients with predisposing cardiac conditions. Eur Heart J 2018;39(7):586–95. https://www.ncbi.nlm.nih.gov/pubmed/29161405
  • Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levison M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007;116(15):1736–54. https://www.ncbi.nlm.nih.gov/pubmed/17446442